Chimeric: Media Thread, page-566

Cost of CarT development, and trying to find a way to secure a new CarT drug to develop are the main reasons they are few and far between.

In short, until CHMs trial into solid tumours, CarT has been wholly targeted at blood cancers. In fact that space is now pretty crowded, so the risk/benefit/cost at looking at more CarT into blood cancers is loosing its shine.

Until the CHM GBM trial results, no CarT drug has shown signs of efficacy into solid tumours. And no cancer drug has shown real efficacy into GBM. Surgery and radiation being the SOC with the use of TMZ. The blood brain barrier, and binding T cells onto a solid tumour is the major hurdle for treatment of GBM. CHM seem to have overcome both of these.

So all the data CHM has shown so far is very impressive. Particularly when this was achieved as a 5th line of treatment.
The phase 1b is being conducted as a 2nd line of treatment. So we should get even better results, hopefully.

The drug in trial now has also shown pre clinical response to several other solid tumour cancer types. And this is important. As GBM has no effective SOC, CHM should hopefully be offered a fast track pathway to approval. Once approved, rolling it into other cancer types by biomarkers or trial can then happen. Hugely increasing its potential value.